Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of a Inotuzumab conjugated via a hydrazone linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage. Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood’s neutral pH environment (pH 7.3-7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0-6.5) and lysosomal (pH 4.5-5.0) compartments of the cell.
Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Pinatuzumab conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds t...

  • Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins...

  • Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MC linker to a MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubuli...